iron succinate

Small moleculeexperimental

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
3

Earliest trial started Jan 1, 2016 (NCT02631668)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • IronSupplementation

    Iron supplementation

Chemistry & pharmacology

Mol. weight
171.92 g/mol
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • butanedioic acid, iron (+2) salt
  • butanedioic acid, iron(2+) salt (1:1)
  • ferromyn
  • ferromyn
  • ferromyn
  • ferrosuccinate
  • ferrous succinate
  • ferrous succinate
  • ferrous succinate
  • ferrous succinate
  • ferrous succinate
  • iron succinate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06830941Phase 4Feb 15, 2025Jiao Tong University
NCT06648018N/AOct 15, 2024Linkoping University
NCT05714007Phase 4Aug 31, 2023Chinese Academy of Medical Sciences, Pharmacosmos
NCT05784870Phase 3Feb 7, 2023Xiamen University
NCT03891277Phase 2Apr 1, 2019Government of China
NCT02631668Phase 4Jan 1, 2016Fudan University
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Chinese Academy of Medical SciencesAcademic/Hospital1112023
Fudan UniversityAcademic/Hospital1112016
Government of ChinaGovernment1112019
Jiao Tong UniversityAcademic/Hospital1112025
Linkoping UniversityAcademic/Hospital1112024
PharmacosmosFor profit1012023
Xiamen UniversityAcademic/Hospital1112023
7 organizations
Page 1 / 1